Analgesia News and Research

RSS

Masimo PVI predicts hemodynamic effects of PEEP in mechanically ventilated patients

Masimo, the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, announced today that a new clinical study published in the March 2010 issue of Anesthesia & Analgesia, shows Masimo PVI successfully predicts the hemodynamic effects of Positive End-Expiratory Pressure in mechanically ventilated patients after cardiac surgery.

1 Apr 2010

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

Pfizer Canada is pleased to announce the recipients of its third Neuropathic Pain Research Awards Competition, which aims to fund and support Canadian innovation within independent neuropathic pain research in the areas of basic biomedical, clinical and health sciences.

31 Mar 2010

Parents’ presence in the recovery room may reduce children’s behavior problems

All parents worry when their child is undergoing surgery and anesthesia. You might assume that children undergoing surgery would be much relieved to find Mom or Dad is there when they wake up—but that's not necessarily the case, according to a study in the April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

31 Mar 2010

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences Inc., announced that it has received ethics board approval to expand enrolment in its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients with myelofibrosis, a chronic debilitating condition, where patient's bone marrow is replaced by scar tissue.

31 Mar 2010

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.

15 Mar 2010

YM Biosciences announces increase of registered direct offering to $17.5M

YM BioSciences Inc., today announced that the previously announced offering of approximately US$15 million has been increased to approximately US$17.5 million.

9 Mar 2010

YM Biosciences to raise $15M in registered direct offering of common stock

YM BioSciences Inc., today announced that it is raising approximately US$15 million in a "registered direct" offering of units at a price of US$1.20 per unit.

5 Mar 2010

Anesthesiologists and health care responders' experience during Wenchuan earthquake in Sichuan

The 2008 earthquake in the Sichuan province of China was among the deadliest in history, killing an estimated 69,000 individuals and leaving millions displaced. Anesthesiologists are critically important medical responders to such disasters, as they have the skills required to resuscitate and stabilize patients while their injuries are surgically treated.

4 Mar 2010

Patients with confirmed episodes of consciousness during surgery have high rates of PTSD: Study

Patients with confirmed episodes of consciousness during surgery have high rates of psychological problems including posttraumatic stress disorder (PTSD), even several years after the incident, reports a study in the March issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

4 Mar 2010

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

YM BioSciences Inc., announces that it filed a Form 6K describing that certain US patents for nimotuzumab licensed to YM's majority-owned Canadian subsidiary , CIMYM BioSciences Inc., have become subject to a lien in the United States, pursuant to a court order, to a third party.

3 Mar 2010

FDA approves CombinatoRx's NDA for Exalgo extended-release tablets

CombinatoRx, Incorporated today announced that the U.S. Food and Drug Administration has approved the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

2 Mar 2010

IARS commits over $1M to anesthesia research to advance the specialty of anesthesiology

The International Anesthesia Research Society announced 10 grant recipients in 2009, committing over $1 million to anesthesia research and other projects that will advance the specialty of anesthesiology. Grant recipients include researchers, clinicians and educators from around the world who have provided outstanding contributions to the anesthesia community.

25 Feb 2010

DURECT, Nycomed amend POSIDUR Development and License Agreement

DURECT Corporation announced today that Nycomed and DURECT have amended the Development and License Agreement entered into between the parties in 2006 covering the development and commercialization of POSIDUR™ (also known as SABER™-Bupivacaine or OPTESIA™), an investigational drug for the treatment of post-surgical pain.

23 Feb 2010

Researchers develop new technique to automatically control anaesthesia during surgical operations

A team of researchers from the Canary Islands has developed a technique for automatically controlling anaesthesia during surgical operations. The new system detects the hypnotic state of the patient at all times and supplies the most appropriate dose of anaesthetic.

19 Feb 2010

SRI International establishes new Neurodegenerative Diseases Research Program

SRI International, an independent nonprofit research and development institute, announced today that a new Neurodegenerative Diseases Research Program has been established within its Center for Health Sciences. This new SRI group of neuroscientists and researchers working at the cutting edge of science brings $6.2 million of funding from the National Institutes of Health (NIH), including the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Environmental Health Sciences (NIEHS), and National Institute of General Medical Sciences (NIGMS).

19 Feb 2010

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults.

18 Feb 2010

Third party reexamination of Phase III study of Ereska meets primary endpoint

Javelin Pharmaceuticals, Inc. today announced that a reexamination conducted by a third party of pain score measurements from its Phase III study of Ereska™ (intranasal ketamine) showed that top line results for its primary endpoint were statistically significant. Previously, Javelin had reported that the top line results for its primary endpoint were not statistically significant.

12 Feb 2010

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

QRxPharma Limited announced today initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone.

11 Feb 2010

YM BioSciences receives additional AeroLEF patents in U.S.

YM BioSciences Inc., announced that it has been granted two additional patents in the US for AeroLEF(R), the Company's proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe acute pain. US patent numbers 7,648,981 and 7,648,982 extend the life of YM's AeroLEF patent estate in the US to 2024.

10 Feb 2010

Analgesia News and Research

Masimo PVI predicts hemodynamic effects of PEEP in mechanically ventilated patients

Recipients of Pfizer Canada's third Neuropathic Pain Research Awards Competition announced

Parents’ presence in the recovery room may reduce children’s behavior problems

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

YM Biosciences announces increase of registered direct offering to $17.5M

YM Biosciences to raise $15M in registered direct offering of common stock

Anesthesiologists and health care responders' experience during Wenchuan earthquake in Sichuan

Patients with confirmed episodes of consciousness during surgery have high rates of PTSD: Study

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

FDA approves CombinatoRx's NDA for Exalgo extended-release tablets

IARS commits over $1M to anesthesia research to advance the specialty of anesthesiology

DURECT, Nycomed amend POSIDUR Development and License Agreement

Researchers develop new technique to automatically control anaesthesia during surgical operations

SRI International establishes new Neurodegenerative Diseases Research Program

Javelin Pharmaceuticals’ Dyloject NDA receives FDA PDUFA date

Third party reexamination of Phase III study of Ereska meets primary endpoint

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

YM BioSciences receives additional AeroLEF patents in U.S.

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News